In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.

Purpose: Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be further improved by replacing the β-emitting lutetium-177 with the α-emi...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Nuclear Medicine & Molecular Imaging Vol. 49; no. 11; pp. 3627 - 3639
Autores principales: Ruigrok, Eline A. M., Tamborino, Giulia, de Blois, Erik, Roobol, Stefan J., Verkaik, Nicole, De Saint-Hubert, Marijke, Konijnenberg, Mark W., van Weerden, Wytske M., de Jong, Marion, Nonnekens, Julie
Formato: Journal Article
Publicado: Springer Nature Sep2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=158671657&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 158671657
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        16197070
        NPC
      jtl: European Journal of Nuclear Medicine & Molecular Imaging
      issn: 16197070
      maglogo: N
    pubinfo:
      dt: Sep2022
      vid: 49
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        158671657
        156825612
        157068957
        10.1007/s00259-022-05821-w
        158671657
      ppf: 3627
      ppct: 12
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
      aug:
        au:
          Ruigrok, Eline A. M.
          Tamborino, Giulia
          de Blois, Erik
          Roobol, Stefan J.
          Verkaik, Nicole
          De Saint-Hubert, Marijke
          Konijnenberg, Mark W.
          van Weerden, Wytske M.
          de Jong, Marion
          Nonnekens, Julie
        affil: Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA, Rotterdam, The Netherlands
      sug:
      ab: Purpose: Targeting the prostate-specific membrane antigen (PSMA) using lutetium-177-labeled PSMA-specific tracers has become a very promising novel therapy option for prostate cancer (PCa). The efficacy of this therapy might be further improved by replacing the β-emitting lutetium-177 with the α-emitting actinium-225. Actinium-225 is thought to have a higher therapeutic efficacy due to the high linear energy transfer (LET) of the emitted α-particles, which can increase the amount and complexity of the therapy induced DNA double strand breaks (DSBs). Here we evaluated the relative biological effectiveness of [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T by assessing in vitro binding characteristics, dosimetry, and therapeutic efficacy. Methods and results: The PSMA-expressing PCa cell line PC3-PIP was used for all in vitro assays. First, binding and displacement assays were performed, which revealed similar binding characteristics between [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T. Next, the assessment of the number of 53BP1 foci, a marker for the number of DNA double strand breaks (DSBs), showed that cells treated with [225Ac]Ac-PSMA-I&T had slower DSB repair kinetics compared to cells treated with [177Lu]Lu-PSMA-I&T. Additionally, clonogenic survival assays showed that specific targeting with [225Ac]Ac-PSMA-I&T and [177Lu]Lu-PSMA-I&T caused a dose-dependent decrease in survival. Lastly, after dosimetric assessment, the relative biological effectiveness (RBE) of [225Ac]Ac-PSMA-I&T was found to be 4.2 times higher compared to [177Lu]Lu-PSMA-I&T. Conclusion: We found that labeling of PSMA-I&T with lutetium-177 or actinium-225 resulted in similar in vitro binding characteristics, indicating that the distinct biological effects observed in this study are not caused by a difference in uptake of the two tracers. The slower repair kinetics of [225Ac]Ac-PSMA-I&T compared to [177Lu]Lu-PSMA-I&T correlates to the assumption that irradiation with actinium-225 causes more complex, more difficult to repair DSBs compared to lutetium-177 irradiation. Furthermore, the higher RBE of [225Ac]Ac-PSMA-I&T compared to [177Lu]Lu-PSMA-I&T underlines the therapeutic potential for the treatment of PCa.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N